EdgeTestMarket TodayOptions TodayIPO
Start free
Stock x Options

LAURUSLABS

Rs 1,969▲ +1.23%
Market closedEquity EOD 11 Sept
52-week rangeThe lowest and highest prices the stock traded at over the last year, from each day's intraday low and high. The marker is today's close: 0% means it sits at the year's low, 100% at the high. It describes where the price is, not where it is going.98.9% up the range
Rs 823Rs 1,982
What Laurus Labs does
A short, human-reviewed summary of the business, written from public sources. Background, not analysis, and not updated intraday.
business summary

Known mainly for antiretroviral (HIV) API manufacturing, ranking among the world's largest suppliers to global ARV drug programs, which historically left it exposed to volatile government and NGO tender pricing. The company has spent recent years diversifying into contract development and manufacturing (CDMO) for global pharma and biotech clients to reduce that dependence.

1
1Sector

Pharma - APIs & CDMO

2
2What it sells

Active pharmaceutical ingredients (APIs), especially for HIV/antiretroviral drugs, finished dosage formulations, and contract development and manufacturing (CDMO) services where it makes drug substances and intermediates for other pharma and biotech companies.

3
3Who buys it

Global generic drugmakers and international ARV drug programs buying bulk HIV APIs, plus pharmaceutical and biotech companies that outsource drug manufacturing to Laurus under CDMO contracts, not retail patients directly.

4
4How it earns

Earns on selling bulk APIs, especially ARVs, to other drugmakers and increasingly on CDMO contracts where global pharma and biotech clients pay for custom drug development and manufacturing. Profit has historically swung with ARV tender pricing, and the company is pushing to grow the steadier, higher-margin CDMO share of revenue.

Implied vs realized volatility
This compares the volatility options are pricing (from the chain) with the volatility the stock has actually delivered. It appears once the live options chain is available.
options live in market hours

The options-implied volatility comes from the live chain, which is available during and around market hours (9:15-3:30 IST, Mon-Fri). The stock has realized 25.1% volatility over the last 30 days; the implied figure and the comparison will show when the chain is live.

LAURUSLABS price vs the biggest options level
The daily candles are the actual stock. The two labeled lines are the single strike with the most call open interest (a resistance level option sellers are defending) and the single strike with the most put open interest (a support level). The full breakdown across every strike is in the Open Interest Profile card below.
EOD 11 Sept
IndicatorsVolume

Loading LAURUSLABS price...

Options snapshot
The live stock option chain (PCR, max pain, expected move, OI) loads during and around market hours.
live in market hours

LAURUSLABS's live option chain - put-call ratio, max pain, expected move and open-interest walls - appears during market hours (9:15-3:30 IST, Mon-Fri). Come back when the market is open for the full options view.

Returns and valuation
Built from the company's own balance sheet and cash flow. Return on equity is the trailing twelve months of profit against the equity on the books; the balance sheet behind it is filed twice a year, not four times.
from the filing as at 2026-03-31
Market cap
Rs 1,06,375 Cr
what the whole company is priced at today
Return on equity
20.1%
profit earned on every Rs 100 of shareholders money
Price to book
20.07x
20.07 times the value on its own books
Return on assets
10.4%
profit against everything it owns
Return on capital
19.7%
EV / EBITDA
59.3x
Dividend yield
0.08%
paid out on today's price
Book value / share
Rs 98
the company's own books, per share
What it owns and what it owes
Straight from the balance sheet in the company's filing. Net debt is borrowings less cash and liquid investments, so a negative figure means it holds more cash than debt.
as at 2026-03-31
Total assets
Rs 10,511 Cr
everything the company owns
Shareholders equity
Rs 5,431 Cr
52% of what it owns is funded by its owners
Cash and equivalents
Rs 113 Cr
cash and near-cash on hand
Net debt
Rs 2,285 Cr
borrowings less cash
Debt to equity
0.44x
borrowings against the owners' money
Current ratio
1.33x
short-term assets against short-term dues

Companies file a balance sheet twice a year, not every quarter, so this is the most recent one published rather than the latest quarter.

The cash it actually made
Profit is an accounting figure; cash flow is what moved. Free cash flow is the cash from running the business less what was spent on plant and equipment, so it is what was left over to pay down debt or return to shareholders.
year to 2026-03-31
Cash from operations
Rs 1,624 Cr
cash the business itself threw off
Free cash flow
Rs 554 Cr
what was left after spending on the business
FCF margin
8.1%
free cash for every Rs 100 of sales
Cash vs profit
1.82x
every rupee of profit arrived as cash, or more

Cash flow is reported for the year to date, so this covers the full period ending 2026-03-31 rather than a single quarter.

Fundamentals
Trailing-twelve-month valuation, margins and growth from the company's own filings.
as of 2026-06-30
P/E (TTM)
97.3
PEG
0.79
EPS (TTM)
Rs 20.2
Net margin
15.0%
Rev growth YoY
+29.10%
Profit growth YoY
+123.94%
TTM revenue
Rs 7,270 Cr
TTM net profit
Rs 1,091 Cr
Against its sector
Where this stock sits within its own sector on each measure. The marker is its position in the peer group and the notch is the sector median. A position is a fact about the cohort, not a view on the stock.
Pharma · 24
P/E97.33vs 37.98 median
Cheapest: NATCOPHARM 12.76Priciest: BIOCON 115.58
Net margin15%vs 14.62% median
Lowest: BIOCON 2.4%Highest: NATCOPHARM 32.85%
Revenue growth29.1%vs 16.3% median
Lowest: NATCOPHARM -44.68%Highest: TORNTPHARM 54.85%
Compared against
ABBOTINDIAAJANTPHARMALKEMAUROPHARMABIOCONCIPLADIVISLABDRREDDYERISGLAXOGLENMARKGRANULESIPCALABJBCHEPHARMLUPINMANKINDNATCOPHARMPFIZERSUNPHARMASYNGENETORNTPHARMWOCKPHARMAZYDUSLIFE

Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.

The business
Sales and net profit from the company's own filings, by financial year or by quarter. Hover any bar for that period's complete figures including operating margin and the change against the comparable earlier period. The single TTM figure above is the sum of the last four quarters.
5 years · 20 quarters
Full financial years - the long arc of the business.
Sales growth
+4.1%
a year, 3 years
Profit growth
+3.9%
a year, 3 years
Operating margin
26.1%
latest year
Sales by financial yearRs 6,813 Cr
Net profit by financial yearRs 890 Cr
FY225 full years · hover a yearFY26

Operating margin has gone from 28.8% to 26.1% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.

Dividends paid
Cash paid per share, from the exchange's corporate-action record, restated to today's share count across bonuses and splits. Dates shown are ex-dates: you must own the shares before that date to receive the payment.
0.06% yield
Rs 60 / year
Paid 10 of 10 yrs
on Rs 1 lakh at today's price · 0.06% yield · Rs 1.2/share
What each year paid, on Rs 1 lakh
15
15
15
56
61
102
61
20
41
61
17
18
19
20
21
22
23
24
25
26*
* 2026 so far - more may still be declared this year

2026 has paid Rs 1.20 per share, about Rs 61 on Rs 1 lakh at today's price. Earlier years are restated to today's share count, so a bonus or split never reads as a dividend cut. Dividends are at the company's discretion and can be cut or skipped.

Large institutional deals
Bulk and block deals reported by the exchange, where a single large trade is disclosed along with the counterparty's name. Only deals above the exchange's disclosure threshold appear here.
last 5
DatePartySideQtyPriceValue
2026-08-31BNP PARIBAS FINANCIAL MARKETSSELL62,72,1751,914.28Rs 1,200.67 Cr
2026-08-31INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.SELL51,34,3611,914.04Rs 982.74 Cr
2026-08-31SOCIETE GENERALESELL28,10,4371,903.84Rs 535.06 Cr
2026-08-31BNP PARIBAS FINANCIAL MARKETSBUY15,3991,860.35Rs 2.86 Cr
2026-08-31INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.BUY1,7181,922.69Rs 0.33 Cr
Technical snapshot
Momentum, trend and delivery-based conviction from the actual price and volume history.
EOD 11 Sept
RSI (14) - momentum
68.3Neutral
0 oversold3070overbought 100
Delivery % - genuine buying vs churn
47%Near average
today 47%20d avg 56.4%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50-DMA
+12.00%
vs 200-DMA
+52.66%
1-month
+6.33%
3-month
+41.81%
1-year
+123.58%
Realized vol (30d)
25.1%
Insider trading disclosures
Promoter, director and other insider trades in the company's own shares, as disclosed to the exchange under SEBI's insider-trading regulations - usually within a few days of the transaction.
last 18 months

Insider trading data unavailable.

Recent announcements
The company's own filings to the exchange - results, board meetings, investor calls - with a link to the source document.
last 6 months

Announcements unavailable.

Want to test a strategy on LAURUSLABS?

Backtest an equity strategy on real market data, free - no card needed.

Start free

Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.